FAQ on Clene's Presentation at the 73rd Emerging Growth Conference
Summary
Clene Inc., a clinical-stage biopharmaceutical company, is set to present at the 73rd Emerging Growth Conference to discuss its innovative treatments for neurodegenerative diseases like ALS and MS, highlighting its commitment to improving mitochondrial health and neuronal function.
What is Clene Inc. and what does it focus on?
Clene Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
When and where is Clene presenting at the Emerging Growth Conference?
Clene is presenting at the 73rd Emerging Growth Conference, scheduled for July 17-18, 2024, with their presentation beginning at 4:45 p.m. EDT on July 18.
Who will be presenting on behalf of Clene at the conference?
Rob Etherington, Clene’s President and CEO, and Morgan Brown, Clene’s CFO, will be giving the presentation.
What is CNM-Au8(R) and what does it do?
CNM-Au8(R) is an investigational first-in-class therapy by Clene that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress.
Where can I find more information about Clene Inc.?
For more information about Clene Inc., please visit their website at www.Clene.com.
How can I view the full press release about Clene’s presentation?
The full press release can be viewed at https://ibn.fm/kt4FO.
What are the implications of Clene’s research for neurodegenerative diseases?
Clene’s research aims to provide innovative treatments for neurodegenerative diseases by improving mitochondrial health and protecting neuronal function, potentially offering new hope for patients with conditions like ALS and MS.
Where is Clene Inc. based?
Clene Inc. is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
Who can I contact for more information about Clene’s presentation or the company?
For more information, you can contact IBN (InvestorBrandNetwork) at 310.299.1717 Office or via email at Editor@InvestorBrandNetwork.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 130107